{"id":775064,"date":"2026-03-04T13:34:13","date_gmt":"2026-03-04T13:34:13","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/775064\/"},"modified":"2026-03-04T13:34:13","modified_gmt":"2026-03-04T13:34:13","slug":"une-nouvelle-voie-therapeutique-ouverte-par-les-medicaments-anti-obesite","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/775064\/","title":{"rendered":"une nouvelle voie th\u00e9rapeutique ouverte par&#8230; les m\u00e9dicaments anti-ob\u00e9sit\u00e9"},"content":{"rendered":"<p>\n    <strong>D\u00c9CRYPTAGE<\/strong> &#8211; La start-up Lilloise 4Moving Biotech propose de repositionner les analogues GLP1 comme traitement pour l\u2019arthrose du genou. Un march\u00e9 en pleine expansion qui se heurte \u00e0 des impasses th\u00e9rapeutiques.<\/p>\n<p class=\"fig-paragraph\">Premi\u00e8re cause mondiale de douleur chronique et de handicap,\u00a0<a href=\"https:\/\/sante.lefigaro.fr\/tags\/arthrose\" target=\"_blank\" data-fig-type=\"Keyword\" rel=\"nofollow noopener\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\">l\u2019arthrose<\/a>\u00a0affecte pr\u00e8s de 10 millions de personnes en France. Cette pathologie exacerb\u00e9e par le vieillissement,\u00a0<a href=\"https:\/\/sante.lefigaro.fr\/sante\/maladie\/obesite\/quelles-causes\" target=\"_blank\" data-fig-type=\"Keyword\" rel=\"nofollow noopener\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\">l\u2019ob\u00e9sit\u00e9<\/a>, la\u00a0<a href=\"https:\/\/www.lefigaro.fr\/sciences\/alerte-sur-la-sedentarite-l-autre-fleau-qui-menace-l-homme-assis-20220220\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\" rel=\"nofollow noopener\" target=\"_blank\">s\u00e9dentarit\u00e9<\/a>\u00a0ou les sports extr\u00eames est en voie d\u2019augmentation, et touche un public de plus en plus jeune. Pourtant, les solutions th\u00e9rapeutiques ne sont pas au rendez-vous.\u00a0<a href=\"http:\/\/sante.lefigaro.fr\/medecine\/arthrose-corticoides-et-anti-inflammatoires-comment-bien-les-utiliser-20241029\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\" rel=\"nofollow noopener\" target=\"_blank\">Les anti-inflammatoires<\/a>\u00a0propos\u00e9s en premi\u00e8re intention apaisent les sympt\u00f4mes dans les meilleurs des cas, mais finissent par perdre leur efficacit\u00e9 ou ne pas \u00eatre tol\u00e9r\u00e9s. \u00ab\u00a0\u00c0 un stade avanc\u00e9 de la maladie, la seule solution propos\u00e9e par la m\u00e9decine est\u00a0<a href=\"http:\/\/sante.lefigaro.fr\/medecine\/arthrose-du-genou-quand-faut-il-envisager-la-pose-d-une-prothese-20250627\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\" rel=\"nofollow noopener\" target=\"_blank\">la proth\u00e8se<\/a> \u00a0\u00bb, explique le Pr\u00a0Francis Berenbaum, chef du service de rhumatologie \u00e0 l\u2019h\u00f4pital Saint-Antoine \u00e0 Paris. Mais cette alternative n\u00e9cessite une chirurgie lourde, pour un b\u00e9n\u00e9fice de seulement quinze ans en moyenne. De plus, dans le cas de l\u2019arthrose du genou, cette solution laisse insatisfaits 20 \u00e0 25\u00a0% des patients concern\u00e9s.<\/p>\n<p class=\"fig-paragraph\">Face \u00e0 cette probl\u00e9matique, les analogues GLP1\u2026<\/p>\n<p class=\"fig-premium-paywall__infos\">\n        Cet article est r\u00e9serv\u00e9 aux abonn\u00e9s.        Il vous reste 79% \u00e0 d\u00e9couvrir.\n    <\/p>\n<p>                <img  data- alt=\"Le Figaro\" class=\"fig-img--complete fig-img\"\/><\/p>\n<p class=\"fig-premium-paywall__title\">Vente Flash<\/p>\n<p class=\"fig-premium-paywall__subtitle\">-70% sur votre abonnement. Sans engagement.<\/p>\n<p class=\"fig-premium-paywall__connect\">\n                D\u00e9j\u00e0 abonn\u00e9\u00a0?                <a class=\"fig-premium-paywall__connect-link\" href=\"https:\/\/connect.lefigaro.fr\/login?client=sante_web&amp;type=main&amp;redirect_uri=https%3A%2F%2Fsante.lefigaro.fr%2Fmedecine%2Farthrose-du-genou-une-nouvelle-voie-therapeutique-ouverte-par-les-nouveaux-medicaments-anti-obesite-20260304\" data-js-gtm=\"{&quot;event&quot;:&quot;customEventGA4&quot;,&quot;eventName&quot;:&quot;click_action&quot;,&quot;feature&quot;:&quot;paywall&quot;,&quot;location&quot;:&quot;paywall&quot;,&quot;button_action&quot;:&quot;connect&quot;,&quot;click_text&quot;:&quot;Connectez-vous&quot;}\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n                    Connectez-vous<br \/>\n                <\/a>\n            <\/p>\n","protected":false},"excerpt":{"rendered":"D\u00c9CRYPTAGE &#8211; La start-up Lilloise 4Moving Biotech propose de repositionner les analogues GLP1 comme traitement pour l\u2019arthrose du&hellip;\n","protected":false},"author":2,"featured_media":775065,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[10],"tags":[29890,1011,27,60577,72,68566,71],"class_list":["post-775064","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sante","tag-arthrose","tag-fr","tag-france","tag-genou","tag-health","tag-rhumatologie","tag-sante"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/116171169497469960","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/775064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=775064"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/775064\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/775065"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=775064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=775064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=775064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}